To examine patients' choices for headache therapies with a self-administered questionnaire involving the Q-No questionnaire for nocebo.
Several newer therapeutic formulations with more
modern mechanisms are invited for the treatment of migraine and headache
developed an explosive environment in the field of medicine. The patients’
perspectives and preferences should be taken into account while prescribing the
medication. In this research, the author determines the patient preferences
along with efficacy and safety data may help physicians to choose the right treatment
for the right person.
To examine patients' choices for headache therapies with
a self-administered questionnaire involving the Q-No questionnaire for nocebo.
A total of 514 patients who naïve to neurostimulation and
monoclonal antibodies have completed the questionnaires.
Patients focused on the treatment's efficacy rather than
the route of administration or safety of the administrated drug. For both acute
and preventive treatment, patients preferred an external neurostimulation
device. For symptomatic pharmaceutical treatment, several patients opt for a
pill than any other medication administered parenterally. For preventive
pharmaceutical treatment, many of the patients go for a pill once per day (52%)
than an injection either intravenously or subcutaneously every month, or three
months. In Q-No questionnaire, 56.6% of out of all participants scored more
than 15, showing potential nocebo behaviours that contributed considerably to
their decisions.
The patient choices along with safety and efficacy
information may assist physicians expertly choose the right therapy for the
right person.
J Headache Pain. 2017 Oct 6;18(1):102
Patients' preferences for headache acute and preventive treatment
Mitsikostas DD et al.
Comments (0)